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Urinary Copper Elevation in a Mouse Model of Wilson’s
Disease Is a Regulated Process to Specifically Decrease
the Hepatic Copper Load
Lawrence W. Gray1, Fangyu Peng2, Shannon A. Molloy3, Venkata S. Pendyala1, Abigael Muchenditsi1,
Otto Muzik4, Jaekwon Lee5, Jack H. Kaplan3, Svetlana Lutsenko1*
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Southwestern Medical Center, Dallas, Texas, United States of America, 3 Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago,
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Abstract
Body copper homeostasis is regulated by the liver, which removes excess copper via bile. In Wilson’s disease (WD), this
function is disrupted due to inactivation of the copper transporter ATP7B resulting in hepatic copper overload. High urinary
copper is a diagnostic feature of WD linked to liver malfunction; the mechanism behind urinary copper elevation is not fully
understood. Using Positron Emission Tomography-Computed Tomography (PET-CT) imaging of live Atp7b2/2 mice at
different stages of disease, a longitudinal metal analysis, and characterization of copper-binding molecules, we show that
urinary copper elevation is a specific regulatory process mediated by distinct molecules. PET-CT and atomic absorption
spectroscopy directly demonstrate an age-dependent decrease in the capacity of Atp7b2/2 livers to accumulate copper,
concomitant with an increase in urinary copper. This reciprocal relationship is specific for copper, indicating that cell
necrosis is not the primary cause for the initial phase of metal elevation in the urine. Instead, the urinary copper increase is
associated with the down-regulation of the copper-transporter Ctr1 in the liver and appearance of a 2 kDa Small Copper
Carrier, SCC, in the urine. SCC is also elevated in the urine of the liver-specific Ctr12/2 knockouts, which have normal ATP7B
function, suggesting that SCC is a normal metabolite carrying copper in the serum. In agreement with this hypothesis,
partially purified SCC-Cu competes with free copper for uptake by Ctr1. Thus, hepatic down-regulation of Ctr1 allows
switching to an SCC-mediated removal of copper via kidney when liver function is impaired. These results demonstrate that
the body regulates copper export through more than one mechanism; better understanding of urinary copper excretion
may contribute to an improved diagnosis and monitoring of WD.
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is the primary route of copper removal and little copper is found in
the urine.
In WD, the copper excretion pattern changes dramatically.
Inactivation of ATP7B impairs copper export into the bile.
Copper content of the liver becomes greatly elevated causing, with
time, significant pathologic changes in liver morphology and
function [2]. Patients with WD also have high urinary copper (208
to 466 mg per day), which serves as an important diagnostic
marker for the disease [4,5]. The origin of high copper in WD
urine is not obvious because most of the incoming copper is
thought to be trapped in the liver. Disease-induced cell necrosis
may result in the release of copper from damaged hepatocytes into
the bloodstream. However, experiments directly testing this
hypothesis are lacking. Furthermore, elevated copper in the urine
is observed in several other conditions (hepatitis, cancer,
pregnancy) [6–8], when ATP7B function is presumed normal,
suggesting existence of a secondary mechanism for copper

Introduction
Copper is an essential trace element that is required for catalytic
activity of key metabolic enzymes involved in oxidative stress
response, respiration, blood clotting, and many other physiologic
processes. Deficit of copper in the diet is associated with cardiac
hypertrophy and neurologic abnormalities, whereas genetically
induced copper insufficiency (in Menkes disease or as a result of
genetic manipulations in animals) is lethal [1]. Although copper is
essential for normal growth and development, excessive copper is
toxic. This toxicity is best illustrated by Wilson’s disease (WD), a
potentially lethal human disease caused by inactivating mutations
in the copper transporter ATP7B and massive copper accumulation in the liver [2]. Normally, in humans and other mammals,
liver is the main organ that maintains copper homeostasis. In
hepatocytes, ATP7B transports excess copper into vesicles for
subsequent excretion into the bile [3]. In a healthy organism, this
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excretion. A better mechanistic understanding of copper elevation
in the urine would facilitate early diagnosis of WD and the
treatment monitoring. Consequently, we utilized the Atp7b2/2
mice, an established model for WD, to investigate the basis of
urinary copper elevation.
Atp7b2/2 mice, like WD patients, accumulate copper first in the
liver and later in other tissues and have a marked liver pathology
[9]. Without intervention of chelation therapy, the disease in these
animals progresses through three major stages. At Stage I (up to 6–
8 weeks after birth), copper accumulates rapidly in the liver and
induces changes in cell cycle machinery and lipid metabolism;
however no major histological changes are apparent [10]. At Stage
II (12–20 weeks), there are numerous metabolic changes, and liver
shows clear signs of inflammation, necrosis, and bile ducts
proliferation. In animals older than 30 weeks (Stage III), there is
a significant recovery of liver morphology and function [11] along
with copper sequestration in highly concentrated deposits,
appearance of regenerating nodules and continuing bile ducts
proliferation [11]. In the present study, we used Atp7b2/2 mice to
show that the loss of ATP7B-mediated copper export also results
in activation of a specific secondary export pathway that
diminishes copper load in the liver. This pathway involves timedependent down-regulation of the copper uptake transporter Ctr1
in the liver and upregulation of a distinct small copper carrier(s),
SCC, in the urine.

Results
Copper in the urine of Atp7b2/2 mice increases with age
but does not directly follow liver pathology
In Atp7b2/2 mice, the liver morphology and function are most
impaired at Stage II of the disease (12–20 weeks of age), and both
parameters are improved in older animals [11]. Consequently, we
tested whether the urinary copper follows liver pathology in
Atp7b2/2 mice by measuring copper concentration and total
copper output in the urine of animals of various ages. In wild-type
mice, urinary copper output and copper concentration were
largely unchanged with some decrease in the total copper output
observed in animals older than 14 weeks. In contrast, the amount
of copper excreted in the urine of Atp7b2/2 mice increased with
age (Figure 1). A marked increase in copper concentration was
detected between 7 and 20 weeks; a statistically significant change
in both concentration and total copper output was most
pronounced at 14–20 weeks (Figure 1). This increase coincides
with marked pathologic changes in the liver [11]. In animals older
than 20 weeks (when copper levels in the liver decreases and liver
morphology and function are partially restored) the amount of
copper in the urine remained high and the total output was similar
to that at 14–20 weeks. Thus, inactivation of Atp7b produces agedependent elevation of copper export through the kidney, which
cannot be fully explained by liver necrosis.

Figure 1. Atp7b inactivation induces age-dependent changes in
urine copper content. (A) Urinary copper concentration and (B) total
amount from wild-type (WT) and Atp7b2/2 (KO) mice at different ages.
Urine collected over 24 hours and measured by atomic absorption.
Data reported as mean concentration 6 SD, n = 3 to 13, animals per age
group. *P,0.05 versus age-matched wild type. Boxplot middle
horizontal bar represents the median; the dotted horizontal line
signifies the mean. The while upper and lower box values signify the
75th and 25th percentiles, whiskers represent the 10th and 90th
percentiles. The black dots represent outliers (three SD from the mean).
doi:10.1371/journal.pone.0038327.g001

explaining the decrease in urinary copper concentration at this
age. Markedly increased urine volume suggested that renal
function was altered in Atp7b2/2 animals older than 20 weeks.
This conclusion was confirmed by measuring protein amounts in
the urine, which revealed proteinuria in Atp7b2/2 mice older than
20 weeks, but not before this age (Figure S1, additional details in
Information S1).

Upregulation of copper export is followed by changes in
renal function
We also noticed that although total copper output was high in
Atp7b2/2 mice older than 20 weeks (Figure 1B), the urinary
concentration of copper of these animals was significantly lower
compared to younger animals (Figure 1A). To gain a better insight
into variations of urinary copper concentration, we measured food
and water intake as well as total urine volume (Figure 2).
Compared to age-matched controls, food (Figure 2B) and water
intake (Figure 2A) did not differ significantly for Atp7b2/2 animals
before 20 weeks; however, after 20 weeks both water intake
(Figure 2A) and urine volume (Figure 2C) increased dramatically,
PLoS ONE | www.plosone.org

Longitudinal PET-CT using 64CuCl2 demonstrates agedependent changes in copper accumulation by
Atp7b2/2 liver
The age-dependent increase of urinary copper suggested that
copper uptake and/or excretion by organs were altered in
Atp7b2/2 animals in an age-dependent manner. To test this
hypothesis we conducted a longitudinal PET imaging of copper
distribution in live Atp7b2/2 mice, who received orally administered 64CuCl2 at 7–8, 13, and 20 weeks of age. We first compared
2
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Figure 2. Renal function is altered in Atp7b2/2 mice older than
20 weeks. Water intake (A), Food intake (B) and urine volume output
(C) relative to age-matched wild-type mice were measured over a 24 hr
period. Double asterisks denote p#0.003. N = 3 to 7 age-matched pairs;
data presented as mean 6 SD; additional supporting data and details in
Figure S1 and information S1.
doi:10.1371/journal.pone.0038327.g002

copper accumulation in the liver at early (2 hours post administration) and late (24 hours post administration) phases (Figure S2
and Figure 3, respectively). At 2 hours, there was no measurable
difference between 64Cu radioactivity in the wild-type and
Atp7b2/2 livers (Figure S2 A, B). However, at 24 hours post
oral administration of 64CuCl2, hepatic 64Cu radioactivity was
noticeably higher in the Atp7b2/2 mice compared to wild-type at
all three ages (Figure 3A and B). Further quantitative analysis of
PET data revealed a significantly higher accumulation/retention
of copper by the Atp7b2/2 liver in younger animals (7–8 weeks)
compared to older animals (Figure 3C), p,0.001. No significant
differences in hepatic copper accumulation were seen in wild-type
animals of different ages (p.0.5).

Age-dependent changes in copper levels in Atp7b2/2
kidneys are inverse to those in the liver and less
pronounced
The apparent decrease in liver’s ability to accumulate copper at
13–20 weeks and a concomitant increase of urinary copper
pointed to the increasing involvement of kidneys in the export of
copper from the body. To better understand the role of kidneys in
copper processing, we performed quantitative PET analysis for
both the kidneys and the bladder. We were able to measure large
mean differences even though animal to animal-to-animal
variation precluded significance. At 2 hours post 64Cu administration, an average 64Cu radioactivity in the Atp7b2/2 kidneys was
consistently lower compared to wild-type at all time-points (Figure
S2). At 24 hours, radioactive copper in Atp7b2/2 kidneys at 7–8
weeks was comparable to that of wild-types, but at 13 and 20
weeks copper levels showed a time-dependent increase and
trended toward higher values than in the age matched wild-types
(Figure 3D). Background 64Cu radioactivity in the intestines made
it difficult to compare actual values; nevertheless, the overall trend
of increasing 64Cu in the bladder of Atp7b2/2 mice with age was
evident and consistent with the atomic absorption (AA) measurements (Figure 3E). No such increase was observed in the bladder of
wild-type mice, again supporting the AA data. It should be noted
that although with increasing age, less 64Cu is found in the
Atp7b2/2 liver and more 64Cu radioactivity is detected in the
Atp7b2/2 kidneys, renal copper levels remain considerably lower
compared to the liver pointing to tissue-specific differences in the
mechanisms of maintaining copper balance (see discussion).

Selective and non-selective phases in urinary copper
elevation
Our studies revealed two phases in elevation of urinary copper
excretion: an initial phase prior to 20 weeks, when urine volume
(and presumably kidney function) were normal, and a later phase
(after 20 weeks) when urine volume was markedly increased. To
understand the mechanism behind initial copper elevation, we
focused on 13–20 weeks animals. We reasoned that elevated
urinary copper along with diminished hepatic retention could be
due to nonspecific leakage of copper from necrotic Atp7b2/2
hepatocytes since necrosis is observed in the Atp7b2/2 liver [11].
Alternatively, a lower retention of copper in the liver and increase
in the urine could be due to specific transport processes such as
PLoS ONE | www.plosone.org
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Figure 3. PET-CT analysis of 64Cu distribution in live mice at 24 hrs after oral administration of 64CuCl2. Representative PET-CT images
of (A) Atp7b2/2 and (B) wild-type mice at 24 hours post oral administration (PO) of 64CuCl2. Orange-brown color denotes 64Cu radioactivity. Red
arrows and white arrows identify liver and gastrointestinal tract 64Cu radioactivity, respectively. (C) Hepatic 64Cu radioactivity in Atp7b2/2 and wildtype mice at 24 hrs PO (p,0.001). Age-dependent 64Cu radioactivity in the (D) kidneys (p = 0.38 for group effect) and (E) urinary bladder of wild-type
and Atp7b2/2 mice at 24 hr PO. %ID/g, percentage of administration dose per gram. Data presented as mean 6 SD. N = 5, number of mice with same
age and genotype. Additional data and details in Figure S2 and Information S1.
doi:10.1371/journal.pone.0038327.g003

molecules with an apparent molecular weight of 2 kDa (Figure 5A).
Subsequent analysis by fractionating CuCl2 (to find elution time
for free copper), tryptophan (to determine elution time for free
amino-acid), and glycyl-L-histidyl-L-lysine copper-binding peptide, GHK (to find elution time for very short peptides)
demonstrated that Cu is neither free ion nor bound to free
amino-acids, since it elutes earlier, i.e. as a larger molecule
(Figure 5C). We hypothesize that the majority of urinary copper
binds to a specific Small Copper Carrier(s), which we named SCC.

reduced copper uptake or facilitated export from the liver into
circulation. To discriminate between these scenarios, we measured
content of several metals in the urine (Figure 4). Specific excretion
was expected to produce a selective increase in copper concentration, whereas a mechanism in which hepatic cell death is the
primary pathway would likely change levels of several metals
[12,13]. ICP-MS analysis confirmed that Cu levels were high in
Atp7b2/2 urine, compared with wild-type and increased with age
(Figure 4A). In contrast, the concentration of all other elements did
not change significantly between 6 and 20 weeks (Figure 4B).
Fluctuations in the total output for all elements but copper showed
strong correlation with the changes in urine volume (Table S1,
additional details in Information S1), whereas copper was elevated
independently of urine volume. Thus, the primary cause of high
copper in the urine prior to 20 weeks is a specific change in the
inter-organ copper fluxes, consistent with the PET data. In
contrast, at 65 weeks of age, all metals showed high levels,
especially iron and zinc (Figure 4C). This non-selective change in
the urinary elemental content was followed by a marked increase
in urine volume and was not explored further.

CTR1 protein levels show specific age-dependent
decrease in the Atp7b2/2 liver, whereas ATP7A is
unchanged
The predominant appearance of copper in one peak indicated
that copper was bound to a single molecule or a limited number of
molecules of a similar size, and implied the involvement of a
specific transporter in this process. ATP7A is a copper transporter
that can be up-regulated in the liver [14] and thus facilitate copper
efflux. Consequently we examined Atp7a expression in the
Atp7b2/2 liver by real-time PCR and western blotting
(Figure 6A,B) when urinary copper levels were near their peak.
We found neither significant change in relative mRNA expression
nor detectable ATP7A protein in the Atp7b2/2 livers. (Figure 6A,B)
We have previously found that the mRNA levels for the copper
transporter Ctr1 are decreased in Atp7b2/2 livers [15]. CTR1 is
primarily responsible for the high-affinity copper uptake by
various tissues, including liver [16]. If the decreased amount of
Ctr1 mRNA is associated with lower protein levels, this would
result in a lower copper uptake, explaining (at least in part) the
PET data. Consequently, we evaluated the CTR1 protein levels in
the wild-type and Atp7b2/2 livers at 6, 13, and 20 weeks by
Western blot (Figure 6C). When compared to the age-matched

Copper in the urine is bound to a Small Copper Carrier
(SCC)
The increase in copper but no other metals raised the question
about the molecular form in which copper is exported into the
urine. To address this issue, we fractionated urinary copper.
Filtering urine through a 3 kDa cut-off filter demonstrated that
more than 74% of copper in wild-type and 83% of copper in the
urine of Atp7b2/2 mice was associated with a low molecular
weight fraction. (i.e. found in the flow-through, Figure 5B). Highresolution size-exclusion chromatography of the 3 kDa cut-off
ultra-filtrate identified urinary copper in a fraction containing

PLoS ONE | www.plosone.org
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weeks. Panels B and C data points (from left to right) represent 6 to 12
weeks, 15 to 20 weeks, and 60 to 65 weeks. Correlation coefficients
found in Table S1.
doi:10.1371/journal.pone.0038327.g004

wild-types, the Atp7b2/2 livers showed age-dependent decrease in
CTR1 protein expression. These changes were specific for the
liver, since similar analysis of kidney samples showed no significant
changes in CTR1 protein compared to those of the wild-type
controls (Figure 6D).

Figure 5. Characterization of urine copper component(s). (A)
Representative graph of gel filtration analysis on 20 ml of Atp7b2/2
urine along with copper levels in resulting fractions. (B) % of total
copper found in the filtrate or retentate of wild-type and Atp7b2/2
urine after application of whole urine to a filter with 3 kDa cutoff. Ages
varied from 6 to 65 weeks. Data presented as % of total copper 6 SD,
n = 21 age-matched wild-type/Atp7b2/2 pairs. (C) Representative graph
of copper profile from gel filtration of 3 kDa filtrate from wild-type and
Atp7b2/2 urine. Arrows point to the elution time of indicated
compounds.
doi:10.1371/journal.pone.0038327.g005

2/2

Figure 4. Elemental content of wild-type and Atp7b
urine
during disease progression. ICP-MS analysis of urine collected over
24 hours from age-matched wild-type and Atp7b2/2 mice. (A)
Comparison of WT and KO copper amounts at different ages. (B) Urine
amounts of Na, Mg, P, K, Ca, Se, and urine volume (relative to wild-type)
at different ages. (C) Amounts of Fe and Zn at different ages (relative to
wild type). N = 2 to 4 age-match WT/KO pairs for each time point. Data
presented as mean 6 SD, **P#0.003. The data points (from left to right)
in Panel A represent 6 weeks, 12 weeks, 15 to 20 weeks, and 60 to 65
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Figure 6. Ctr1 and Atp7A levels in the liver and kidney of Atp7b2/2 and wild-type mice. (A) Real-time PCR analysis of Atp7A mRNA levels
in the liver of wild-type and Atp7b2/2 mice at different ages. Data presented as mean 6 SD, n = 3 to 4 different samples of each genotype and age.
(B) Representative Western blot illustrating ATP7A protein expression in the livers of wild-type and Atp7b2/2 mice at 7 and 20 weeks. Twenty weeks
old Atp7b2/2 kidneys were used as a positive control for ATP7A protein expression. ‘‘ST’’ denotes molecular weight standards. Black arrow points to
ATP7A band. Weak bands in the liver samples are due to non-specific staining (C, D) Quantitation of CTR1 protein levels by Western blot analysis and
densitometry (relative to wild type) in liver and kidneys of wild-type and Atp7b2/2 mice at different ages. Band intensity in each sample was
normalized to a b-actin loading control. Data presented as mean 6 SD. n = 2 for each genotype per age group.
doi:10.1371/journal.pone.0038327.g006

sera, copper-bound small molecular weight complexes, such as
copper-bound chelators, do not elute with their apparent
molecular weight in gel filtration chromatography but rather
associate with higher-molecular weight proteins, data not shown).
Consequently, to examine whether SCC can transfer copper to
CTR1 we measured competition between Cu-SCC and free Cu
using 64Cu uptake assays in HEK293 cells stably over-expressing
CTR1. Identical volume from the corresponding elution fraction
of the wild-type urine served as a control. 64Cu uptake was
gradually reduced in the presence of increasing amounts of SCC
from KO urine. No such competition was seen using the wild-type
fractions (Figure 7B).

Liver-specific down-regulation of CTR1 is associated with
the elevation of copper-bound SCC in the urine
The apparent correlation between CTR1 down-regulation in
the liver and elevation of SCC in the urine suggested that these
events might be linked. Specifically, we hypothesized that SCC
could be a normal source of exchangeable copper in the serum
and that Cu-SCC became elevated in the urine because less CTR1
is available to accept copper from SCC and transport into
hepatocytes. To test this hypothesis, we examined the urinary
copper components of mice that have normal Atp7b, but lack Ctr1
specifically in the liver. These animals do not have liver disease yet
have elevated urinary copper [16]. Gel filtration analysis of urine
from the liver –specific Ctr1 knock-out mice showed a single peak
of elevated copper that has the same elution time as SCC from
Atp7b2/2 mice (Figure 7A).

SCC competes with radioactive

64

Discussion
Genetic mutations in the copper transporter ATP7B disrupt
biliary copper excretion resulting in a massive hepatic copper
accumulation and Wilson’s disease (WD). Using Atp7b2/2 mice,
an animal model for WD, we demonstrate that Atp7b inactivation
also up-regulates an available but underutilized secondary
pathway for copper removal from the body, which produces a
clinically well-known phenomenon of high urinary copper in WD
patients. Atp7b2/2 mice show an age-dependent increase of
urinary copper that does not directly follow known changes in liver
pathology. This increase is selective for copper in animals under
20 weeks of age, which strongly suggests that urinary copper
excretion is a specific mechanism to protect against hepatic copper

Cu for uptake via CTR1

To further test our hypothesis that SCC represents a source of
exchangeable copper in the serum, we measured total and
exchangeable copper in wild-type and Atp7b2/2 serum at 20
weeks and attempted to detect SCC in the serum. We observed an
increase in a fraction of exchangeable copper in Atp7b2/2 serum
compared to wild-type (Figure S3, additional details Information
S1), however we were unable to directly link it to SCC,
presumably due to the association of serum copper with a fraction
of high-molecular weight proteins (we found that in the mouse
PLoS ONE | www.plosone.org
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copper in the kidney, renal copper overload is modest compared to
the liver. This is likely due to the presence in kidneys of another
copper-transporter, ATP7A, which is likely to facilitate copper
release partially compensating for the loss of ATP7B function [20].
We have found that copper in the urine is bound to a previously
unknown small carrier, SCC, with an apparent molecular weight
of 2 kDa; SCC is larger than free amino-acids or the tripeptide
GHK, but smaller than metallothionein. Sensitivity of copperbound SCC to pH and organic solvents has complicated
purification using standard protocols, and we are developing
new approaches for SCC identification. Importantly, a similar
small copper carrier complex is present at lower levels in wild-type
urine, which suggest a role for SCC in normal copper metabolism.
One such role could be copper sequestration and excretion via
renal filtration when hepatic copper uptake is saturated. However,
the SCC’s ability to compete with 64Cu for uptake via CTR1
strongly suggests that its normal physiological function could also
be to deliver copper to cells. The highly similar copper profiles of
urine from the Atp7b2/2 and liver-specific Ctr12/2 mice further
illustrates a functional interaction between SCC and CTR1.
Hepatic copper homeostasis is normally achieved by regulation
of copper uptake (CTR1), sequestration (MT), and export
(ATP7B). In the absence of ATP7B, MT levels are significantly
elevated in WD patients and Atp7b2/2 mice [10] yet elevation of
MT alone cannot explain why copper is shuttled away from the
liver as disease progresses. It was suggested in the literature that
WD hepatocytes may release the MT-Cu complex [21], however
our data are inconsistent with this hypothesis. ATP7A, which is
not ordinarily seen in the adult mouse liver, under certain
conditions can be upregulated in the liver [14] and pump copper
across the basolateral surface back into the blood. Increased
ATP7A levels could readily explain the age-dependent increase in
serum copper levels observed in Atp7b2/2 mice [11]. In the
Atp7b2/2 mice, we previously documented elevation of ATP7A in
the kidney and brain, where ATP7A is assumed to replace some of
the biosynthetic functions of ATP7B [20,22]. Additionally, specific
genetic ablation of Ctr1 in the heart, results in the elevation of
ATP7A in the adult mouse liver [14]. However, in the liver of
Atp7b2/2 mice we did not find any changes in ATP7A protein or
mRNA expression. These results agree with the PET data,
showing higher copper retention in Atp7b2/2 liver at all timepoints despite time-dependent decrease of copper uptake transporter, Ctr1.
Walshe has insightfully suggested that in WD patients copper
retention by the liver decreases as disease progresses [14].
Longitudinal PET-CT imaging of live Atp7b2/2 animals allowed
direct measurements of copper accumulation in their liver at
different ages and tested this hypothesis. It is apparent that
radioactive copper found in the liver 24 hours post injection
decreases with age. The major copper entry pathway into the liver
is through CTR1. CTR1 is known to be regulated by copper at
the level of protein stability [23], trafficking [24–26], and
transcription [27,28]. We found in the Atp7b2/2 mouse liver,
CTR1 protein and mRNA levels decrease in an age-dependent
manner. The ablation of Ctr1 specifically in the liver of mice does
not induce visible pathology in the liver, but is associated with
elevation of urinary copper and no other metals [16]. Since no
other metal increases in the urine prior to 20 weeks of age, we have
concluded that down-regulation of CTR1 and increased filtration
of SCC (rather than hepatocytes death) are primarily responsible
for the initial phase of urinary copper elevation.
In is important to emphasize that our results do not exclude
some contribution of copper from necrotic cells and may reflect a
situation when the disease is relatively mild. In humans, the course

Figure 7. Functional interaction of SCC and CTR1. (A) Copper
concentrations in fractions obtained from gel filtration of wild-type,
Atp7b2/2, and liver-specific Ctr12/2 urine. (B) 64Cu uptake assay by
HEK293 cells stably overexpressing hCtr1 in the presence of increasing
concentrations of gel filtration purified SCC from urine of Atp7b2/2 and
wild-type mice. Radioactive copper-64 was kept constant at 0.25 mM.
Sodium phosphate buffer pH 7.4 was used as the buffer control. 16 is
equal to a copper concentration of 0.25 mM for Atp7b2/2 SCC and 26to
206 are multiples of the original 16 concentration. The volumes used
for the assays were set to achieve the desired 16to 206concentrations
specifically for Atp7b2/2 SCC. The wild-type SCC 16 to 206 assays are
done with the same volumes of SCC utilized for corresponding
Atp7b2/2 SCC assays, thus wild-type concentrations used are low due
to inherent lower copper levels in WT SCC. Data presented as mean 6
SD, performed in triplicates. See Figure S3.
doi:10.1371/journal.pone.0038327.g007

overload. A similar increase in urinary copper has been
documented in WD patients as they transition from asymptomatic
to symptomatic stage of the disease [5].
Older Atp7b2/2 mice show changes of several metal ions and a
markedly increased urine volume. This latter change is associated
with an increased water intake and proteinuria, suggestive of
glomerular damage. The time-dependent kidney damage could be
either due to increased amounts of copper being filtered through
kidney or, more likely, due to inactivation of renal Atp7b and
copper misbalance in kidney cells. Atp7b is normally expressed in
kidneys at relatively high levels [17–19] and inactivation of Atp7b is
likely to alter normal copper homeostasis. It is interesting that
despite loss of ATP7B function and gradual accumulation of
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7006 g for 15 minutes to remove debris and the supernatant was
spun at 22,0006 g for 35 minutes to obtain a membrane pellet.
The pellet was then dissolved in the Laemmli gel sample buffer.
For SDS-PAGE, 1 mg and 25 mg of membrane protein were
separated on 7.5% and 4–20% polyacrylamide gels to analyze
Atp7A and Ctr1, respectively. Proteins were transferred onto
polyvinyldifluoride (PVDF) membrane and probed with rabbit
anti-CTR1 (1:1000) and rabbit anti-ATP7A (1:500) antibody.
Staining was detected by goat anti-rabbit HRP secondary
antibody (Santa Cruz Biotechnology, 1:20,000) and HRP-conjugated anti-mouse b-actin (Sigma,1:10,000) using West Pico
Chemiluminescence (Pierce) according to the manufacturer’s
instructions. Staining with anti-b-actin antibody was used as a
loading control. Band intensity was measured with Image J and
quantified after normalization to b-actin.

of WD varies greatly from mild inflammation to a sudden liver
failure. Whether the origin and/or molecular identity of urinary
copper are the same in these conditions is unclear. The LPP rats,
another model of WD, die invariably from liver failure that was
linked to mitochondria destruction [29]. Mitochondria matrix
contains a small copper ligand CuL [30], which upon mitochondria rupture and cell necrosis would presumably be released. In
Atp7b2/2 mice, the course of disease does not include liver failure
and the selective mechanism discussed in present work better
accommodates our results. Further characterization of coppercarrying small molecules will greatly contribute to our understanding of hepatic copper homeostasis and may help WD
diagnosis and monitoring.
In conclusion, elevated urinary copper in Atp7b2/2 mice is the
result of a redundant and copper-selective mechanism based upon
homeostatic control of CTR1 that is turned on to maintain
systemic copper balance when liver copper homeostasis is
compromised. The redirection of copper flow from the liver to
kidneys in WD is mediated by a small copper carrier SCC, which
is distinct from free amino acids, tripeptide GHK, or a full-length
metallothionein. Functional interactions between SCC and CTR1
may control copper distribution between tissues.

Longitudinal PET-CT
The PET imaging experiments were conducted under the
protocol approved by the Institutional Animal Care and Use
Committee, UT Southwestern Medical Center at Dallas. The
mice were administered with 64CuCl2 [74 kBq (2 mCi)/g body
weight] in a volume of 25 ml by oral feeding. The dose of 64CuCl2
supplied in 0.1 N HCl was diluted in 25 ml of normal saline
containing 0.9% sodium chloride. PET of the mice was performed
with a Siemens Inveon microPET/CT system, using a protocol
published recently [32]. Briefly, the mice were anesthetized using
3% isoflurane at room temperature and placed in spread-supine
position on the imaging bed under 2% isoflurane anesthesia for the
duration of the imaging. Static whole body imaging was performed
at 2 and 24 hours post oral administration of the tracer,
respectively, which consisted of two overlapping frames of
15 min duration for each frame. As part of the PET imaging
protocol, CT data was acquired (80 kV, 500 mA) for attenuation
correction and anatomical localization. PET images were subsequently reconstructed using the 3D OSEM algorithm and scatter
as well as attenuation correction. All images were analyzed using
the Inveon Research Workplace (IRW) software (Siemens).
Following re-slicing of fused PET/CT images into arbitrary views,
regions of interest (ROIs) for liver, kidneys, and urinary bladder
were drawn to obtain quantitative measurements of the 64Cu
tracer activity expressed as percentage of administration dose per
gram (%ID/g).

Materials and Methods
Materials
Doubly deionized water (ddH2O) was used in preparation of
buffers and reagents. All buffers were treated with metal-ion
chelating agent, Chelex 100 (Bio-Rad) prior to use then
subsequently vacuumed degassed and filtered on a 0.45 mM
FHLC filter (Millipore). Gel filtration standards were from BioRad Laboratories.

Animal husbandry and urine collection
Urine was collected from Atp7b knockout (Atp7b2/2), Ctr1
knockout and wild-type (WT) littermate control mice. The
generation of these mice was previously described [16,31]. The
animals were housed at the Johns Hopkins University School of
Medicine Animal Care Facility according to National Institute of
Health guidelines. For urine collection, age matched Atp7b2/2 and
WT mice of both genders were placed for 48 hours in individual
metabolic cages (Tecniplast). Animals were allowed to acclimate to
their new environment for the first 24 hours, and then urine was
collected for the subsequent 24 hour period. During collection, the
mice had free access to food and water. Urine volume as well as
water and food intake were measured. The urine was centrifuged
at 4,0006g for 5 minutes at 4uC to remove debris. Urine was
either used immediately or stored at 280uC. The above
experimental protocols were approved by the Institutional Animal
Care and Use Committee (IACUC) of JHU. Urine collection from
the liver specific Ctr12/2 mice was performed as previously
described [16] using protocols approved by the IACUC of
University of Nebraska-Lincoln. Subsequent analysis of urine
from both animal strains was performed under identical conditions, as described below.

Size-Exclusion Chromatography of urine filtrates
Urine was ultrafiltered on a Microcon YM-3 (MWCO 3000,
Bedford MA) at 14,0006g for 200 min at 4uC. One hundred
microliters of urine filtrate was loaded onto a size-exclusion
column (Phenomenex Bio-Sep S-2000, 7.56200, 10 mM), equilibrated with 50 mM sodium phosphate buffer, pH 7.5. Samples
were fractionated isocratically with the same buffer at a flow rate
of 0.5 ml per min, and 0.5 ml fractions were collected over
50 minutes. Absorbance was monitored at 215 and 280 nm.
Calibration of size exclusion column was done using molecular
weight standards (Bio-Rad, Thyroglobulin 670 KDa; c-globulin
158 KDa; Ovalbumin 44 KDa; Myoglobin 17 KDa; Vitamin B12
1,350 Da), reduced L-glutathione (307 Da), tryptophan
(,204 Da), Copper Chloride (,64 Da). All standards were
prepared in 50 mM sodium phosphate buffer pH 7.5.

Tissue preparation and analysis
Tissues were dissected after whole animal perfusion with
phosphate-buffered saline (pH 7.4; PBS), frozen in liquid nitrogen,
and stored at 280uC until use. Protein extracts were prepared on
ice by homogenizing liver and kidney in the lysis buffer (50 mM
Hepes (pH 7.4), 0.1% Igepal,150 mM NaCl, 1 mM AEBSF,
250 mM sucrose) containing EDTA-free protease inhibitor
cocktail (Roche). The tissue homogenates were centrifuged at
PLoS ONE | www.plosone.org

Atomic Absorption Spectrophotometry
The copper concentration of the urine, filtrate, and in the
chromatography fractions was determined using a Shimadzu 6650
graphite furnace atomic absorption spectrophotometer (AA)
equipped with an ASC-6100 autosampler. Briefly, samples were
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diluted with ddH2O (1:10 or 1:500 for fractionated and
unfractionated urine, respectively) to be in the linear absorption
range of the calibration curve [1–10 parts per billion (ppb)]. Each
sample was measured 2 to 3 times, and the concentration of
copper was derived by comparing absorption with a calibration
curve. All values are reported as means.

halted by the addition of ice-cold stop buffer (150 mM NaCl,
5 mM KCl, 2.5 mM MgCl2̧ 10 mM EDTA, 25 mM Hepes,
pH 7.4) to the cells; they were subsequently washed twice with
stop buffer. The cells were then lysed in lysis buffer (0.4% Triton
X-100, 5 mM DTT, 20 mM Tris pH 8 and 2 mM EDTA) and an
aliquot of the cell lysate was added to EcoLume Scintillation fluid
and counted using a Beckman LS 6500 scintillation counter. The
protein concentration of the cell lysate was calculated after
radioactive decay and the copper uptake per well was calculated as
pmoles Cu/mg protein/min and the average of triplicate
measurements per treatment were expressed as pmoles Cu/mg
protein/min.

Inductively coupled plasma mass spectrometry (ICP MS)
Analysis was performed using an Agilent 77006 equipped with
an ASX 250 autosampler. The system is operated at a radio
frequency power of 1550 W, an argon plasma gas flow rate of
15 L/min, Ar carrier gas flow rate of 1.04 L/min. All elements
were measured in kinetic energy discrimination (KED) mode using
He gas (4.3 ml/min). Urine samples were diluted into 1% HNO3,
(trace metal grade, Fisher Scientific). Data were quantified using a
10-point calibration curve (0–5000 ppb (ng/L)) with external
standards for Na, Mg, P, K, Ca, Fe, Cu, Zn, in 1% HNO3, (to
match the sample matrix). For each sample, data were acquired in
triplicates and averaged. An internal standard was used to correct
for plasma instabilities and differences in total ion concentrations,
triplicate measurements of a 10 ppb Cu solution as well as a blank
(containing diluent only) was used as quality control. To ensure
maximum recovery of elements from the sample certified NIST
standard reference materials (serum (SRM 1598a), and water
(SRM 1643e)) were prepared and analyzed by the same method as
the samples. Time-points presented in Figure 4 represent different
ages of mice plotted as one time point; the ‘‘6 week’’ time-point
represents the average of data for 6–12 week old urine, the ‘‘15
week’’ timepoint is the average of 15–20 week samples, and the 60
week timepoint is the average of 60–65 week old urine. Four agematched wild-type/Atp7b2/2 pairs were used to generate data for
each of the 6 and 15 timepoints; two age-matched wild-type/
Atp7b2/2 pairs were used for the 60 week time-point.

Statistical analysis
Values are expressed as mean 6 SD. Statistical significance was
evaluated using unpaired t-test and among more than two groups
by analysis of one-way ANOVA. Differences were considered
significant at p,0.05. PET quantitative values are expressed as
mean of %ID/g 6 SD. In order to assess significant differences in
64
Cu tracer activity among liver, kidneys, and urinary bladder
between Atp7b2/2 and C57BL wild-type mice, a 26 (3) mixeddesign analysis was conducted, where the between-subjects factor
represents the group (Atp7b2/2, C57BL mice) and the withinsubjects factor represents the three time-points (7–8, 13, 20 weeks).
Analyses were performed separately for the 3 regions of interest
(liver, kidneys, urinary bladder). The overall test was subsequently
followed-up by post-hoc unpaired t-tests between the two groups
for individual time-points. A p value,0.05 was considered to
represent statistical significance. Box plot outliers were determined
by multiplying the interquartile range by 1.5 and subtracting the
obtained value from either the first quartile or third quartile, to
determine the lower and upper limits; all measurements beyond
these limits are considered outliers.

Real-Time PCR

Supporting Information

Total RNA was isolated from 100 mg of mouse liver using
Trizol Reagent (Invitrogen). RNA quality was assessed by Agilent
2100 Bioanalyzer with all samples having RIN values greater than
8.6. For real-time PCR, cDNA was synthesized with QuantiTect
Reverse Transcription Kit (Qiagen) from 1 mg of RNA. The target
and control genes were amplified in 20 mL reactions using Applied
Biosystems (ABI) Taq-Man Universal PCR Master Mix and TaqMan gene expression primers on an ABI 7500 Real-time PCR
system. RT-PCR data was analyzed using the DDCT method.
GAPDH was used for normalization.
Copper uptake. HEK293 cells containing tetracycline-regulated N-Terminal FLAG-tagged hCTR1 was previously described
[33]. The cells were grown at 37uC and 5% CO2 in DMEM
(Mediatech) containing 10% FBS (Atlanta Biologicals), 25 mM
Hepes and 1% PSF (Invitrogen) with the following selective
antibiotics: 10 mg/ml blasticidin and 400 mg/ml hygromycin B.
hCTR1 protein expression was induced by the addition of 1 mg/
ml of tetracycline to the medium for 48 hours.
One day prior to Cu uptake assay HEK/hCTR1-FLAG tagged
cells were seeded onto 12-well tissue culture plates at a density of
0.66106 cells/well. Prior to the uptake assay the media was
removed from the cells and replaced with transport media,
DMEM+10%FBS, to which either gel filtration fraction of
Atp7b2/2 urine was added at 0.25–5 mM Cu or the same volume
of the fractionated wild-type urine was added in a final volume of
0.5 ml. Control cells were those to which no urine sample was
added. Copper uptake was performed by the addition of at
0.25 mM CuCl2 containing 64Cu (Washington University, St.
Louis, MO) to the cells for 45 minutes at 37uC. Cu uptake was
PLoS ONE | www.plosone.org

Figure S1 Related to Figure 2: Proteinuria is apparent
in Atp7b2/2 mice older than 20 weeks. Comparison of
protein amounts from urine of Atp7b2/2 and wildtype mice at
different ages. The solid horizontal bar within in the box
represents the median, while upper and lower bars signify the
75th and 25th percentiles, respectively. The dotted horizontal line
signifies the mean. The whiskers represent the 10th and 90th
percentiles. The black dots represent outliers. #P value = 0.088.
See supporting information for experimental details (Information
S1).
(TIF)
Figure S2 Related to Figure 3. Representative PET-CT

imaging and quantitative analysis of wildtype and Atp7b2/2 mice
at 2 hours post oral administration of 64Cu. Pet-CT images of (A)
wildtype and (B) Atp7b2/2 mice at indicated ages. Quantitative
analysis of radioactivity of (C) liver and (D) kidneys of wildtype and
Atp7b2/2 mice at indicated ages (p = 0.27 for group effect). Data
presented as mean 6 SD. n = 5, per genotype. Red arrows
indicate the position of the liver and white arrows indicate 64Cu
radioactivity in the gastrointestinal tract.
(TIF)
Related to Figure 7: Exchangeable copper in
the serum of wild-type and Atp7b2/2 mice. Data presented
as mean 6 SD. n = 2 per genotype. See supporting information for
experimental details (Information S1).
(TIF)
Figure S3
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Table S1 Related to Figure 4: Correlation between
changes in urine volume and amounts of urinary
elements with disease progression. *Spearman ranked
coefficients with significance p,0.05. n = 6. See supporting
information for description of statistical analysis (Information S1).
(DOCX)
Information S1
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